Table 1.
Pre-treatment demographic and clinical characteristics of the study population.
| Patient Characteristics | Number of Patients (%) |
|---|---|
| No of patients: n = 84 females | 84 (100%) |
| Age at diagnosis (years) | |
| <55 | 40 (48%) |
| ≥55 | 44 (52%) |
| BMI kg/m2 according to WHO criteria: | |
| Normal weight (<24.99) | 39 (46%) |
| Overweight (≥25–29.99) | 30 (36%) |
| Obese (30 or more) | 15 (18%) |
| Menopausal status: | |
| Pre-menopausal | 27 (32%) |
| Post-menopausal | 57 (68%) |
| Parity: | |
| Nulliparous/1–2 children/≥3 children | 6 (7%)/62 (74%)/16 (19%) |
| Tumour characteristics | |
| Tumour diameters | |
| T1 (a, b, c < 2 cm)/ T2 (≥2 cm, but <5 cm) | 55 (65%)/29 (35%) |
| Nodal status (N): | |
| N0/N1 | 64 (76%)/20 (24%) |
| Metastases (M) | None |
| Stage (TNM classifications) | |
| IA/IIA/IIB | 40 (48%)/38 (45%)/6 (7%) |
| Histopathological grade: | |
| Grade 1/ Grade 2/ Grade 3 | 6 (7%)/67 (80%)/11 (13%) |
| Histological diagnosis: | |
| Invasive ductal carcinoma (IDC) | 73 (87%) |
| Invasive lobular carcinoma (ILC) | 11 (13%) |
| Intrinsic subtype | |
| Luminal A (ER+/PR+/HER2−/Ki-67 < 20%) | 51 (61%) |
| Luminal B HER2 negative
(ER+/PR+/HER2−/Ki-67 ≥ 20%) |
16 (19%) |
| Luminal B HER2 positive
(ER+/PR+/HER2+/Ki-67- all %) |
7 (8%) |
| Non-luminal HER2 positive (ER-/PR-/HER2+/Ki-67- all %) |
2 (2%) |
| Triple-negative (ER-/PR-/HER2-/Ki-67- all %) | 8 (10%) |
| ER status | |
| positive/negative | 74 (88%)/10 (12%) |
| PR status | |
| positive/negative | 68 (81%)/16 (19%) |
| HER2 status | |
| positive/negative | 9 (10%)/75 (90%) |
| Ki67 expression | |
| <20%/>20% | 45 (54%)/39 (46%) |
| Laterality: | |
| Left breast/Right breast | 45 (54%)/39 (46%) |
BMI—body mass index; WHO—World Health Organization; TNM classifications—Tumour diameter (T), Nodal status (N), Metastases (M); ER—oestrogen receptor; PR—progesterone receptor; HER-2—human epidermal growth factor receptor 2; Ki-67—proliferation marker.